Related Experiment Video
Updated: Aug 27, 2025
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
WNT-modulating gene silencers as a gene therapy for osteoporosis, bone fracture, and critical-sized bone defects
Won-Taek Oh1, Yeon-Suk Yang2, Jun Xie3
1Department of Medicine, Division of Rheumatology, University of Massachusetts Chan Medical School, 364 Plantation Street. LRB 217, Worcester, MA 01605, USA; Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul 03722, Korea.
Abstract:
Treating osteoporosis and associated bone fractures remains challenging for drug development in part due to potential off-target side effects and the requirement for long-term treatment. Here, we identify recombinant adeno-associated virus (rAAV)-mediated gene therapy as a complementary approach to existing osteoporosis therapies, offering long-lasting targeting of multiple targets and/or previously undruggable intracellular non-enzymatic targets. Treatment with a bone-targeted rAAV carrying artificial microRNAs (miRNAs) silenced the expression of WNT antagonists, schnurri-3 (SHN3), and sclerostin (SOST), and enhanced WNT/β-catenin signaling, osteoblast function, and bone formation. A single systemic administration of rAAVs effectively reversed bone loss in both postmenopausal and senile osteoporosis. Moreover, the healing of bone fracture and critical-sized bone defects was also markedly improved by systemic injection or transplantation of AAV-bound allograft bone to the osteotomy sites. Collectively, our data demonstrate the clinical potential of bone-specific gene silencers to treat skeletal disorders of low bone mass and impaired fracture repair.
Insights
Gene therapy using recombinant adeno-associated virus (rAAV) offers a novel approach for osteoporosis. This bone-targeted therapy effectively reversed bone loss and improved fracture healing in preclinical models.
Area of Science:
- Regenerative Medicine
- Gene Therapy
- Skeletal Biology
Background:
- Osteoporosis treatment faces challenges due to side effects and long-term requirements.
- Gene therapy presents a complementary approach for osteoporosis, enabling long-lasting targeting of intracellular targets.
Purpose of the Study:
- To evaluate recombinant adeno-associated virus (rAAV)-mediated gene therapy for osteoporosis and bone fracture repair.
- To investigate the efficacy of bone-targeted rAAV carrying artificial microRNAs (miRNAs) to silence WNT antagonists.
Main Methods:
- Treatment with bone-targeted rAAV carrying artificial miRNAs to silence schnurri-3 (SHN3) and sclerostin (SOST).
- Systemic administration of rAAVs in models of postmenopausal and senile osteoporosis.
- Assessment of fracture healing and critical-sized bone defects following rAAV treatment.
Main Results:
- rAAV gene therapy successfully silenced SHN3 and SOST, enhancing WNT/β-catenin signaling, osteoblast function, and bone formation.
- A single rAAV administration reversed bone loss in osteoporosis models.
- Bone fracture and defect healing were significantly improved by rAAV treatment.
Conclusions:
- rAAV-mediated gene therapy is a promising approach for treating skeletal disorders like osteoporosis.
- Bone-specific gene silencers delivered via rAAV demonstrate clinical potential for low bone mass and impaired fracture repair.
More Related Videos
Related Concept Videos
02:54Canonical Wnt Signaling Pathway
01:41Non-Canonical Wnt Signaling Pathways
01:27Fractures: Bone Repair
Minor fractures with no bone displacement are treated by immobilizing the fractured bone using a cast or splint. However, in the case of fractures with displaced bones, the broken bones are repositioned before immobilization to ensure successful healing without deformation and loss of function. The realignment of fractured bone ends is performed through a process called reduction. If the...
01:40Bone Remodeling
00:59Gene Therapy